Related Image: University of Chicago launches research program in catastrophic deformation |
...cancer-causing virus influences a key signaling pa...This stimulates the cells to divide, helping the v... researchers at Ohio State University, examined th... protein that it produces called p12. , The resear...AIDS Research and Human Retroviruses. , The study...
...hool of Medicine have identified a link between a ...(EBV) protein known to be expressed in a number of...e a new mechanism by which EBV transforms human B ... which can lead to development of B-cell lymphomas... Microbiology and Director of Tumor Virology, with...
...gion that annually suffers from low oxygen which c... much earlier this year, meaning it could be poten...adversely than normal, researchers are reporting. ...ty, Texas A&M at Galveston, Louisiana State Un...in the northern Gulf of Mexico and their findings ...
...policy announced earlier this week , this time fr...Med Central welcomes the announcement of the US Na...s policy. The NIH calls on all of its grantees to ...esearch in the National Library of Medicine,s PubM...2 months. , BioMed Central anticipates that many ...
Other Biology News:Viral protein influences key cell-signaling pathway 2Viral protein influences key cell-signaling pathway 3Defensins neutralize anthrax toxin 2Dead zone area in Gulf could be increasing, researchers say 2BioMed Central welcomes the new National Institutes of Health public access policy 2(Date:7/3/2008)... IRVINE, Calif., July 3 /- Antigen...ics Inc.), a leader in high throughput,antigen/bio...omics tools,announced today that the Company was ...e of Allergy and Infectious Diseases (NIAID) and t...The $3 million grant will,fund efforts to further ...
(Date:7/2/2008)... Boston Scientific only company to offer choice o...rug-eluting stent platforms, NATICK, Mass., July ...oration (NYSE: BSX ) today announced that the U.S...the PROMUS(TM) Everolimus-Eluting,Coronary Stent S.... The,PROMUS Stent is a private-labeled XIENCE(TM)...
(Date:7/2/2008)... XIENCE V, Only Drug Eluting Stent to Demonstr...cal Trials, Now Available in United States for ..., ABBOTT PARK, Ill., July 2 /PRNewswire-FirstCall... Drug Administration (FDA) approved the,XIENCE(TM)...e treatment of,coronary artery disease. XIENCE V i...
(Date:7/2/2008)... Auburn University,s Harrison School of Pha...ert Systems into Retail Pharmacy Teaching ... July 2 /- InforMedix Holdi... announce that Auburn,University,s Harrison School...dix,s Med-eMonitor and Med-eXpert Systems into its...
Breaking Biology Technology:Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 2Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 3Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System 4FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 2FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 3FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 4FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 5Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedix's Med-eXpert(TM) System 2Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedix's Med-eXpert(TM) System 3Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedix's Med-eXpert(TM) System 4...gram , ,MADISON, Wis. Alfalight, Inc. , a Wiscon...strated 65 percent total power conversion efficien... Albuquerque, N.M. This step toward the eventual g...Defense Advanced Research Projects Agency s Super...ithin the U.S. Department of Defense. , ,The progr...
... formed a scientific advisory board to guide the c... , ,Announced last week by President and Chief Exe...ist of distinguished scientific leaders who will h...e within Quintessence Biosciences, Inc. They will ...d evaluates its drug development plan, including t...
... do , ,MADISON The human aspect of leveraging an...patient safety in health care is often overshadowe...os and gadgets. Jeffrey Grossman MD , president ...isconsin Medical Foundation, spoke Wednesday at th...ced by the Wisconsin Technology Network. Dr Grossm...
...address how IT can be leveraged to improve patient...and companies lead the nation in this effort. , ,... information errors or a lack of data lead to as m...ng figure in mind, the Wisconsin Technology Networ...onference June 22-23 at the Fluno Center in Madiso...
Other Biology Technology:Alfalight increases laser efficiency for DOD program 2Quintessence Biosciences forms cancer therapeutic advisory board 2UW Medical Foundation CEO shares his vision on the state of health care and patient safety 2UW Medical Foundation CEO shares his vision on the state of health care and patient safety 3Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology 2Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology 3Rabbit monoclonal [EP282Y] to Asparagine synthetase ( Abpromise for all tested applications). Antigen: Synthetic peptide corresponding to residues in the C-terminus of Human Asparagine synthetas
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications).
Biology Products: